LCL161 sensitivity patterns were supported by mechanistic analyses of the drug targets and TNF-α signaling, indicating target engagement and a potential for response prediction by RIPK1 gene expression levels, consistent with previously published clinical data in breast cancer [38]. Here, RIPK1 is linked to breast cancer.